Plus   Neg

Stock Alert: AC Immune Tanks 40% As Alzheimer's Drug Fails To Meet Primary Endpoint

Shares of AC Immune SA (ACIU) are losing over 40% on Wednesday morning after its mid-stage study evaluating Semorinemab in early alzheimer's disease failed to meet primary goals.

ACIU is currently trading at $4.96, down $3.76 or 43.12%, on the Nasdaq.

AC Immune said its partner Genentech, a member of the Roche Group, has informed top line results from a Phase 2 trial of the anti-Tau antibody, semorinemab, in early Alzheimer's disease which show that semorinemab did not meet its primary efficacy endpoint of reducing decline on Clinical Dementia Rating-Sum of Boxes compared to placebo.

Two secondary endpoints, Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 and Alzheimer's Disease Cooperative Study Group - Activities of Daily Living Inventory were also not met.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform U.S. airline Delta Air Lines, Inc. and its Italian codeshare partner Alitalia are planning to launch quarantine-free, COVID-free flights between U.S. and Europe through new testing protocols, starting in December. In a statement, Delta said it has signed deals with airports and governments eliminating quarantine requirements on COVID-tested flights connecting Atlanta and Rome.
Follow RTT